- \n
- \n
Management characterizes the current period as a pivotal evolution with a significantly lowered risk profile following the ANNAFILM Complete Response Letter (CRL).<\/p>\n<\/li>\n
- \n
Performance attribution for the quarter was driven by a 10% revenue increase in manufacturing and supply, specifically from Suboxone and ONDEEF, despite a slight full-year decline due to prior-year one-time deferred revenue recognition.<\/p>\n<\/li>\n
- \n
The company has rapidly addressed CRL requirements within 31 days by contracting CROs, modifying packaging for easier opening, and finalizing protocols for human factors and PK studies.<\/p>\n<\/li>\n
- \n
Strategic positioning has shifted to prioritize ANNAFILM as the primary growth driver, leading to a decision to out-license Libervant in the U.S. to focus resources on the epinephrine launch.<\/p>\n<\/li>\n
- \n
The clinical team was significantly strengthened with the addition of world-renowned allergist Dr. Matt Greenhawk and seasoned development leader Dr. Matthew Davis to lead FDA interactions.<\/p>\n<\/li>\n
- \n
Management settled a nine-year defamation lawsuit, which they described as a strategic move to remove a long-standing distraction and simplify the company’s legal workload.<\/p>\n<\/li>\n
- \n
The commercial strategy now includes a 50% increase in the planned sales force (from 50 to 75 reps) to deepen penetration into the allergist and high-decile pediatrician markets.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
The company is committed to resubmitting the ANNAFILM NDA in the third quarter of 2026, assuming a successful Type A meeting with the FDA within the next 30 days.<\/p>\n<\/li>\n
- \n
Financial guidance for 2026 projects total revenue of $46,000,000 to $50,000,000 and an adjusted EBITDA loss of $30,000,000 to $35,000,000, excluding potential launch costs.<\/p>\n<\/li>\n
- \n
The RTW revenue-sharing agreement extension to June 2027 provides a capital safety net for the commercial launch, which management expects to be close to cash neutral by 2027.<\/p>\n<\/li>\n
- \n
International expansion remains a priority with planned regulatory filings for ANNAFILM in Europe and Canada before the end of 2026, following the U.S. resubmission.<\/p>\n<\/li>\n
- \n
The AQST-108 prodrug platform is expected to produce top-line clinical data in the near future, though its development timeline is secondary to the ANNAFILM launch.<\/p>\n<\/li>\n<\/ul>\n
- \n
- \n
RTW extended their $75,000,000 revenue-sharing agreement and made an additional $5,000,000 strategic equity investment, signaling institutional confidence.<\/p>\n<\/li>\n
- \n
The company ended 2025 with $121,200,000 in cash, which management believes provides sufficient runway for all 2026 development and regulatory objectives.<\/p>\n<\/li>\n
- \n
Aquestive successfully defended its data package as the FDA denied a competitor’s citizen petition, which management views as a validating regulatory milestone.<\/p>\n<\/li>\n
- \n
The decision to increase the sales force to 75 reps is intended to eliminate ‘white space’ in geographic coverage and improve efficiency by reducing representative travel time.<\/p>\n<\/li>\n<\/ul><\/div>\n
- \n
- \n